A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Inclusion Criteria

• •1. Patient with histologically/cytologically confirmed diagnosis of any of the subtypes of B-cell NHL or T-cell NHL defined below as documented by medical records and with histology based on criteria established by the World Health Organization (Swerdlow 2017)
• •2. Relapsed or refractory patient who is refractory or intolerant to standard therapy or for whom, in the opinion of the investigator, there is no appropriate treatment for the primary disease.
• •3. Patient who has measurable disease
• •4. Eastern Cooperative Oncology Group Performance Status 0 to 2
• •5. Life expectancy of at least 3 months
• •3. Prior treatment with a MALT1 inhibitor
• •4. Patient is unable to swallow tablets